293 results on '"Liebisch, Peter"'
Search Results
2. Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial
3. Full or intensity‐reduced high‐dose melphalan and single or double autologous stem cell transplant with or without bortezomib consolidation in patients with newly diagnosed multiple myeloma
4. Targeted sequencing using a 47 gene multiple myeloma mutation panel (M3P) in -17p high risk disease
5. Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom)
6. Prognostic significance of serum cystatin C in multiple myeloma
7. RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses
8. DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma
9. Kinetics of Renal Function during Induction in Newly Diagnosed Multiple Myeloma: Results of Two Prospective Studies by the German Myeloma Study Group DSMM
10. A time resolved iron-specific x-ray absorption experiment yields no evidence for an Fe(super 2+) -> Fe(super 3+) transition during Q(sub A)(super -) -> Q(sub B) electron transfer in the photosynthetic reaction center
11. X-ray absorption spectroscopy to analyze nuclear geometry and electronic structure of biological metal centers—potential and questions examined with special focus on the tetra-nuclear manganese complex of oxygenic photosynthesis
12. The G-Allele of the PSMA6−8C>G polymorphism is associated with poor outcome in multiple myeloma independently of circulating proteasome serum levels
13. Patterns of Renal Recovery and Toxicity with Novel Agent-Based Induction Triplets in Newly Diagnosed Multiple Myeloma - an Analysis of Two Prospective Studies By the German DSMM Myeloma Study Group
14. Detection of renal impairment as one specific comorbidity factor in multiple myeloma: multicenter study in 198 consecutive patients
15. Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma
16. Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma
17. Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation
18. Value of comparative genomic hybridization and fluorescence in situ hybridization for molecular diagnostics in multiple myeloma
19. Follow-up of patients with progressive multiple myeloma undergoing allografts after reduced-intensity conditioning
20. Bortezomib consolidation following autologous transplant in younger and older patients with newly diagnosed multiple myeloma in two phase III trials
21. Allogeneic Transplantation in Multiple Myeloma: Long-Term Follow-Up and Cytogenetic Subgroup Analysis
22. Stellungnahme zur Nutzenbewertung des G-BA von Arzneimitteln für seltene Leiden gemäß § 35a SGB V, veröffentlicht am 4. Januar 2016, Vorgangsnummer 2015-10-01-D-108, QWiG Bericht Nr. 349
23. Stellungnahme zur Nutzenbewertung des G-BA von Arzneimitteln für seltene Leiden gemäß § 35a SGB V, veröffentlicht am 15. März 2016, Vorgangsnummer 2015-12-15-D-203, IQWiG Bericht Nr. 367
24. Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders
25. Bortezomib Consolidation Following Autologous Transplant Equalizes the Outcome for Older Patients with Less Intensive Pretreatment Compared to Younger Patients with Newly Diagnosed Multiple Myeloma
26. Stellungnahme zur Nutzenbewertung gemäß § 35a SGB V, Vorgangsnummer 2015-09-01-D-177, IQWiG Bericht Nr. 343, veröffentlicht am 27. November 2015
27. Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis
28. Hydrogen-induced structural changes at the nickel site of the regulatory [NiFe] hydrogenase from Ralstonia eutropha detected by X-ray absorption spectroscopy
29. Autotransplant with and without induction chemotherapy in older multiple myeloma patients: long-term outcome of a randomized trial
30. Stellungnahme zur Nutzenbewertung des G-BA von Arzneimitteln für seltene Leiden gemäß § 35a SGB V, veröffentlicht am 02. Dezember 2013, Vorgangsnummer 2013-09-01-D-075, IQWiG Bericht Nr. 195
31. The G-Allele of the PSMA6-8C>G polymorphism is associated with poor outcome in multiple myeloma independently of circulating proteasome serum levels
32. Outcome and Prognostic Factors of 17p Deleted Multiple Myeloma Patients
33. Autologous Followed By Allogeneic Versus Tandem-Autologous Stem Cell Transplant in Newly Diagnosed FISH-del13q Myeloma
34. Survival Analysis in Patients with Multiple Myeloma after Allogeneic Hematopoietic Stem Cell Transplantation, a Single Center Study (1994-2013)
35. Targeted sequencing using a 47 gene multiple myeloma mutation panel (M3P) in -17p high risk disease
36. Der Mangankomplex der Photosynthese im katalytischen Zyklus
37. Expression of Cereblon (CRBN) Is Associated with Disease Stage, Genetic Subgroups and Specific Micro-RNAs in Multiple Myeloma
38. Prognostic Impact of Chromosomal Abnormalities In Elderly Patients with Multiple Myeloma Treated with High-Dose Melphalan (MEL140) and Autologous Stem Cell Transplantation
39. IDH1 and IDH2 mutations are Not Frequent In Multiple Myeloma
40. Linear Dichroism in the XANES of Partially Oriented Samples: Theory and Application to the Photosynthetic Manganese Complex
41. OPTIMUM Dose of Thalidomide for Relapsed Multiple Myeloma.
42. Velcade, Intravenous Cyclophosphamide and Dexamethasone (VCD) Induction for Previously Untreated Multiple Myeloma (German DSMM XIa Trial).
43. Allogeneic Stem Cell Transplant Versus Tandem High-Dose Melphalan for Front-Line Treatment of Deletion 13q14 Myeloma – An Interim Analysis of the German DSMM V Trial.
44. Diagnostic Utility of the B-cell Lineage Markers CD20, CD79a, PAX5, and CD19 in Paraffin-embedded Tissues From Lymphoid Neoplasms
45. Incorporation of the Bone Marker Carboxy-Terminal Telopeptide of Type-1 Collagen (ICTP) into a Combined ISS-ICTP Score Improves the Prognostic Significance of the ISS in Newly Diagnosed Symptomatic Multiple Myeloma and Identifies a Very Low Risk Group Which Has No Benefit from High-Dose Therapy
46. Lenalidomide, Adriamycin and Dexamethason (RAD) in Relapsed and Refractory Multiple Myeloma: Final Results from a Phase I/II Trial of “Deutsche Studiengruppe Multiples Myelom”
47. A Functional Promoter Polymorphism (−8C>G) of the Proteasome Subunit α6 Gene Is Associated with Multiple Myeloma and Poor Outcome Independent of Circulating Proteasome Serum Levels.
48. Bortezomib, Intravenous Cyclophosphamide and Dexamethasone (VelCD) for Previously Untreated Multiple Myeloma: An Interim Analysis of the German DSMM XIa Trial
49. Association of Elevated Circulating Proteasome Levels at Diagnosis with Poor Outcome in Multiple Myeloma
50. Detection of Renal Impairment (RI) as One Specific Comorbidity Factor in Multiple Myeloma (MM) Patients: Multi-Center Study in 198 Consecutive Patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.